Amsterdam - Delayed Quote EUR

FAGR.AS,0P0000ENSW,0 (FAGR.AS)

6.42

0.00

(0.00%)

At close: July 23 at 10:00:00 PM GMT+2

Fagron increases share capital through exercise subscription rights

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 85,000 new shares have been issued on 6 June 2025. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 504,303,905.59. The total number of shares with voting rights after the issue amounts to 73,31

GlobeNewswire 4 days ago

ARSUF
Fagron shareholders approve all voting items AGM

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 May 2025 – 7PM CET Fagron shareholders approve all voting items AGM Fagron, the leading global player in pharmaceutical compounding, held its annual general shareholders meeting today, where all the voting items were approved. ResolutionsThe annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.35 per share for the fiscal year 2024, the remuneration policy and

GlobeNewswire 29 days ago

ARSUF
Fagron publishes agenda for 2025 annual shareholders meeting

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2025 – 8 AM CET Fagron publishes agenda for 2025 annual shareholders meeting The Board of Directors of Fagron NV invites shareholders to attend Fagron’s annual general meeting of shareholders on Monday 12 May 2025. AgendaThe agenda includes the discussion of the annual report, the approval of the annual financial statements and the dividend proposal of €0.35 for the financial year 2024, and the approval of the remunera

GlobeNewswire last month

ARSUF
Fagron to present its upgraded growth strategy and mid-term financial targets at its Capital Markets Day 2025

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2025 – 7AM CET Fagron to present its upgraded growth strategy and mid-term financial targets at its Capital Markets Day 2025 Fagron, the leading global player in pharmaceutical compounding will host its Capital Markets Day 2025 today from 2PM CET. The event will include presentations from CEO Rafael Padilla and CFO Karin de Jong, as well as regional and functional leaders. The Company will provide an update on its stra

GlobeNewswire last month

ARSUF
Record first-quarter revenue of €239 million, reflecting 14% topline growth

Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2025 – 7:00 AM CET Record first-quarter revenue of €239 million, reflecting 14% topline growth Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2025. Key Highlights Revenue maintained its strong growth momentum, increasing 14.1% on reported basis to €238.7 million (15.2% at CER), with all regions and segments contr

GlobeNewswire last month

ARSUF
Fagron publishes its annual report 2024

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2025 – 7AM CET Fagron publishes its annual report 2024 Fagron, the leading global player in pharmaceutical compounding, today publishes its annual report 2024. Discussion of the annual report and the approval of the financial statements will be put on the agenda of the annual general meeting of shareholders scheduled for 12 May 2025. The annual report is available in the official Dutch version and i

GlobeNewswire 3 months ago

ARSUF
Fagron delivers exceptional performance with 14% topline growth and 17% increase in REBITDA for FY 2024

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 20 February 2025 – 7AM CET Fagron delivers exceptional performance with 14% topline growth and 17% increase in REBITDA for FY 2024 Fagron, the leading global player in pharmaceutical compounding, today publishes its full year results for the period ending 31 December 2024. Key Highlights Exceptional topline performance with 14.3% reported growth (15.9% at CER) and 13.0% organic growth at CER, driven by all

GlobeNewswire 3 months ago

ARSUF
Fagron solidifies its leadership position with the acquisition of Guinama in Spain

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 4 Feb 2025 – 7AM CET Fagron solidifies its leadership position with the acquisition of Guinama in Spain Fagron, the leading global player in pharmaceutical compounding is pleased to announce the acquisition of Guinama in Spain. This acquisition underscores Fagron’s commitment to expanding across our key markets whilst adhering to our disciplined acquisition strategy. Guinama, based in Valencia, Spain, specializes in repackaging

GlobeNewswire 4 months ago

ARSUF
Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 7 Jan 2025 – 7AM CET Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil Fagron, the leading global player in pharmaceutical compounding is pleased to announce the signing of two strategic acquisitions: CareFirst Specialty Pharmacy in North America and Injeplast in Brazil. These acquisitions underscore Fagron’s commitment to expanding across our key markets whils

GlobeNewswire 4 months ago

ARSUF
Fagron updates on FDA communication regarding the June 2024 inspection at Wichita

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 23 Dec 2024 – 7AM CET Fagron updates on FDA communication regarding the June 2024 inspection at Wichita Following the FDA’s routine inspection at Fagron’s Wichita facility conducted in June 2024, the Company received a warning letter from the FDA (Warning Letter) on December 19, 2024. The Warning Letter requires Fagron to enhance processes for investigating discrepancies, and validations of future manufactu

GlobeNewswire 5 months ago

ARSUF
Disclosure of notification received from FMR LLC

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 November 2024 – 6.45 PM CET Disclosure of notification received from FMR LLC Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from FMR LLC. Notification by FMR LLC On 21 November 2024, Fagron received a notification that the shareholding of Fidelity Management & Research Company LLC, a controlled undertaking of FMR LLC, crossed the

GlobeNewswire 6 months ago

ARSUF
Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook

Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 – 7:00 AM CET Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2024. Key Highlights Continued topline momentum with 12.1% reported revenue growth (15.7% at CER) and 12.2% organic growth at C

GlobeNewswire 7 months ago

ARSUF
Disclosure of notification received from AOC Pharma S.à r.l.

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 8 October 2024 – 9:00 PM CET Disclosure of notification received from AOC Pharma S.à r.l. Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from AOC Pharma S.à r.l. Notification by AOC Pharma S.à r.l. On 3 October 2024, Fagron received a notification that changes took place in the chain of controlled undertakings through which the share

GlobeNewswire 7 months ago

ARSUF
Fagron completes share buy-back program

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 September 2024 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program today. In the last period from 9 September 2024 through 13 September 2024, Fagron purchased 45,000 of its owns shares at an average price of € 19.10 per share corresponding to a total amount of € 859,324.10. A total of 150,000 Fagron shares have been repurchased under the buy-back program at an averag

GlobeNewswire 8 months ago

ARSUF
Fagron’s share buy-back program: Weekly update

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 September 2024 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 2 September 2024 through 6 September 2024, Fagron purchased 33,500 of its owns shares at an average price of € 19.17 per share corresponding to a total amount of € 642,302.02. These purchases are part of the share buy-back program of up to 150,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme, which

GlobeNewswire 8 months ago

ARSUF
Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024

Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 1 August 2024 – 7:00 AM CET Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2024. Key Highlights Strong topline performance with 15.5% reported revenue growth (15.3% at Constant Exchange Rates (CER)) and 12.8% o

GlobeNewswire 10 months ago

ARSUF

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

FAGR.AS,0P0000ENSW,0 (FAGR.AS)

Fagron increases share capital through exercise subscription rights

Fagron shareholders approve all voting items AGM

Fagron publishes agenda for 2025 annual shareholders meeting

Fagron to present its upgraded growth strategy and mid-term financial targets at its Capital Markets Day 2025

Record first-quarter revenue of €239 million, reflecting 14% topline growth

Fagron publishes its annual report 2024

Fagron delivers exceptional performance with 14% topline growth and 17% increase in REBITDA for FY 2024

Fagron solidifies its leadership position with the acquisition of Guinama in Spain

Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil

Fagron updates on FDA communication regarding the June 2024 inspection at Wichita

Disclosure of notification received from FMR LLC

Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook

Disclosure of notification received from AOC Pharma S.à r.l.

Fagron completes share buy-back program

Fagron’s share buy-back program: Weekly update

Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024